Role of Parasitic Infection in Inflammatory Bowel Disease and Irritable Bowel Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04760600

Enrollment

300

Registered

2021-02-18

Start date

2021-06-30

Completion date

2024-06-30

Last updated

2021-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parasite IBS IBD

Brief summary

Role of parasitic infection in Inflammatory bowel disease and Irritable bowel The burden of the parasitic disease is in-direct relation with the health and nutritional status of the host, inducing not only parasite-specific immunity but also can modify the host's immune responses . Many parasites can imitate inflammatory bowel disorders and some studies showed that infection with parasites can improve disorders like IBD or moderate the symptoms of inflammatory bowel disorders . Even though, many studies have shown that gastrointestinal infection is an important risk factor for the development of IBS

Detailed description

1. Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD) and Irritable bowel syndrome (IBS) in comparison with control subjects. 2. Evaluating the effect of the parasite on the course and prognosis of the diseases. 3. Evaluating the effect of the antiparasitic drugs on the course and prognosis of the diseases.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

17 Years to 69 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of IBD will be confirmed using 1. standard clinical, 2. endoscopic, 3. radiographic and4 pathological criteria according to the Montreal classification of the extent and severity of IBD * Diagnosis of IBS will depend on Rome IV criteria 1. Recurrent abdominal pain on average at least 1 day/week in the last 3 months, 2. associated with two or more of the following criteria: 3. Related to defecation; 4. Associated with a change in the frequency of stool and/ or Associated with a change in the form (appearance) of stool.

Exclusion criteria

* any patient who received antipiotic or antiparasitic drug within the past 4 weeks

Design outcomes

Primary

Measure	Time frame	Description
Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD) and Irritable bowel syndrome (IBS) in comparison with control subjects.	baseline	Detect the prevalence of parasite/s associated with Inflammatory bowel diseases (IBD) and Irritable bowel syndrome (IBS) in comparison with control subjects.by making stool analysis and clinical examination

Secondary

Measure	Time frame	Description
measure the effect of the antiparasitic drugs on the course and prognosis of the diseases	baseline	giving the patient antiparasitic drug and measure the effect of anti parasitic drug on course and prognosis of disease

Countries

Egypt

Contacts

Primary Contactmarina shawqi, md

gm161059@gmail.com01276121351

Backup Contactlamia galal

lamiazak@gmail.com01003143075

Outcome results